• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体内结直肠癌奥沙利铂联合口服氟嘧啶 S-1 的化疗疗效。

Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.

机构信息

Oncology Medical Affairs Department, Tokushima Research Center, Tokushima, Japan.

出版信息

Anticancer Res. 2012 Jul;32(7):2807-12.

PMID:22753741
Abstract

Oxaliplatin is effective when used with 5-fluorouracil (5-FU) and leucovorin, or with capecitabine (COX) for the treatment of colorectal cancer. In this experiment, we investigated the optimal combination schedule and antitumor activity of oral S-1 with oxaliplatin combination therapy (SOX) against human colorectal cancer xenografts in vivo. Using human colon cancer COL-1-bearing nude mice, oxaliplatin was administered at a total dose of 8.3 mg/kg on day 1 alone, on day 8 alone, or in divided doses administered on days 1 and 8 with S-1 (6.9 mg/kg, days 1-14). The antitumor activity of SOX, administered according to the divided schedule was significantly superior to both monotherapies (p<0.01), and the toxicity was tolerable. However, administration on day 8 alone failed to significantly increase the antitumor activity, when compared with that of monotherapy, while administration on day 1 alone was toxic in this model. Next, the efficacy of SOX was compared with that of COX (360 mg/kg, days 1-14). The antitumor effect of SOX was significantly superior to that of COX (p<0.01), with an equivalent toxicity; moreover SOX suppressed COL-1 tumor growth for a longer period of time (2.2 times) than did COX. The antitumor activity of SOX against the 5-FU-resistant colorectal cancer cell line KM12C/5-FU was equivalent to that of COX. The evaluation of intermittent SOX administration in a clinical trial might be of critical value.

摘要

奥沙利铂与氟尿嘧啶(5-FU)和亚叶酸联合应用,或与卡培他滨(COX)联合应用于结直肠癌的治疗是有效的。在这项实验中,我们研究了 S-1 联合奥沙利铂(SOX)组合疗法在体内对人结直肠癌细胞异种移植物的最佳联合方案和抗肿瘤活性。用人结肠癌 COL-1 荷瘤裸鼠,奥沙利铂单独在第 1 天给予总量 8.3mg/kg,单独在第 8 天给予,或在第 1 天和第 8 天给予 S-1(6.9mg/kg,第 1-14 天)分剂量给予。根据分剂量方案给予的 SOX 的抗肿瘤活性明显优于单药治疗(p<0.01),且毒性可耐受。然而,与单药治疗相比,第 8 天单独给药并不能显著增加抗肿瘤活性,而在该模型中,第 1 天单独给药则具有毒性。接下来,将 SOX 的疗效与 COX(360mg/kg,第 1-14 天)进行比较。SOX 的抗肿瘤作用明显优于 COX(p<0.01),毒性相当;此外,SOX 抑制 COL-1 肿瘤生长的时间(2.2 倍)长于 COX。SOX 对 5-FU 耐药结直肠癌细胞系 KM12C/5-FU 的抗肿瘤活性与 COX 相当。在临床试验中评估间歇性 SOX 给药可能具有重要价值。

相似文献

1
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.体内结直肠癌奥沙利铂联合口服氟嘧啶 S-1 的化疗疗效。
Anticancer Res. 2012 Jul;32(7):2807-12.
2
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.奥沙利铂增强卡培他滨对人结直肠癌和胃癌异种移植瘤的疗效。
Oncol Rep. 2007 Oct;18(4):775-8.
3
Oral fluoropyrimidine treatment of colorectal cancer.口服氟嘧啶治疗结直肠癌。
Clin Colorectal Cancer. 2001 Aug;1(2):95-103. doi: 10.3816/CCC.2001.n.009.
4
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.一项 S-1-奥沙利铂与卡培他滨-奥沙利铂治疗晚期胃癌的随机 II 期试验。
Eur J Cancer. 2012 Mar;48(4):518-26. doi: 10.1016/j.ejca.2011.12.017. Epub 2012 Jan 12.
5
Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.贝伐单抗联合卡培他滨和奥沙利铂在人结直肠癌异种移植模型中的抗肿瘤活性。
Oncol Rep. 2009 Aug;22(2):241-7.
6
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.S-1联合奥沙利铂对比卡培他滨联合奥沙利铂用于转移性结直肠癌患者一线治疗:一项3期试验的更新结果
BMC Cancer. 2014 Nov 26;14:883. doi: 10.1186/1471-2407-14-883.
7
Capecitabine plus oxaliplatin for the treatment of colorectal cancer.卡培他滨联合奥沙利铂治疗结直肠癌。
Expert Rev Anticancer Ther. 2008 Feb;8(2):161-74. doi: 10.1586/14737140.8.2.161.
8
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.厄洛替尼与卡培他滨联合应用在人肿瘤异种移植模型中的抗肿瘤活性。
Cancer Chemother Pharmacol. 2006 May;57(5):693-702. doi: 10.1007/s00280-005-0079-3. Epub 2005 Dec 16.
9
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.奥沙利铂联合口服 S-1 或卡培他滨一线治疗转移性结直肠癌患者的可行性研究。
Anticancer Res. 2013 Sep;33(9):4029-32.
10
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.XELOX方案(卡培他滨联合奥沙利铂):转移性结直肠癌患者的一线有效治疗方案。
J Clin Oncol. 2004 Jun 1;22(11):2084-91. doi: 10.1200/JCO.2004.11.069.

引用本文的文献

1
The Prognostic Significance of 5-Fluorouracil Induced Inflammation and Immuno-Modulation in Colorectal Cancer Patients.5-氟尿嘧啶诱导的炎症和免疫调节在结直肠癌患者中的预后意义
J Inflamm Res. 2020 Dec 31;13:1245-1259. doi: 10.2147/JIR.S283069. eCollection 2020.
2
A case of severe megacolon due to acquired isolated hypoganglionosis after low anterior resection for lower rectal cancer.低位直肠癌前切除术后获得性孤立性副神经节发育不良致重度巨结肠 1 例。
Clin J Gastroenterol. 2020 Jun;13(3):328-333. doi: 10.1007/s12328-019-01079-2. Epub 2019 Dec 11.
3
Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
抗间皮素重组免疫毒素治疗结直肠癌。
Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1. doi: 10.1016/j.clcc.2019.06.006. Epub 2019 Jul 2.
4
The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo.小分子 C19 与 KRAS4b-PDEδ 复合物结合并增强其稳定性,在体外和体内抑制结直肠癌细胞的生长。
BMC Cancer. 2018 Nov 1;18(1):1056. doi: 10.1186/s12885-018-4968-3.
5
Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis.预防化疗和放疗引起的口腔黏膜炎的辅助治疗
Integr Cancer Ther. 2018 Dec;17(4):1027-1047. doi: 10.1177/1534735418794885. Epub 2018 Aug 23.
6
Variety Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model.多种益生菌在同基因结直肠癌模型中预防性减轻5-氟尿嘧啶/奥沙利铂诱导的肠道损伤。
Front Microbiol. 2018 May 15;9:983. doi: 10.3389/fmicb.2018.00983. eCollection 2018.
7
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.化疗药物在结直肠癌中的胃肠道毒性:炎症的作用。
World J Gastroenterol. 2014 Apr 14;20(14):3751-61. doi: 10.3748/wjg.v20.i14.3751.
8
Increase of phosphatase and tensin homolog by silymarin to inhibit human pharynx squamous cancer.水飞蓟宾通过抑制人咽鳞癌细胞中磷酸酶和张力蛋白同源物的表达而发挥作用。
J Med Food. 2013 Sep;16(9):778-84. doi: 10.1089/jmf.2012.2534. Epub 2013 Aug 3.